The objectives of the National Center of Competence in Research (NCCR) "AntiResist" are to search for new antibiotics and to develop alternative strategies to combat antibiotic-resistant pathogens. "AntiResist" is one of a…
Michael N. Hall receives the Balzan Prize for his groundbreaking contributions to our understanding of the molecular mechanisms that regulate cell growth and ageing. Michael Hall discovered two proteins, TOR1 and TOR2, which…
The distinguished jury announced that Prof. Marek Basler from the Biozentrum, University of Basel, will receive the Sanofi-Institut Pasteur International Junior Award this year together with Prof. Ido Amit, Weizmann…
The Biozentrum start-up Aukera Therapeutics was selected to join the BaseLaunch Accelerator Program. With its qualification for this program, the biotech venture receives funding of up to 500,000 Swiss francs as well as…
A number of pathogens protect themselves with an outer membrane that makes it difficult to combat them with antibiotics. In addition, the widespread use of antibiotics promotes the development of resistant bacteria. In…
CV of Prof. Dr. Alex Schier ORCID 0000-0001-7645-5325 Google Scholar Google Scholar Nationality: Swiss/US Positions: Director of the Biozentrum, University of Basel Since 2018 Visiting Professor, Department of Molecular and…
The Team Prof. Markus Rüegg, PhD, CEO and Member of the Board Training in biochemistry and neurosciences Proven track record in neuromuscular research Full Professor for neurobiology Thomas Meier, PhD Chairman of the Board…
Join us! Are you interested in becoming part of the team? Feel free to contact us anytime! We are looking for highly motivated and curious PhD students with a background in theoretical physics, computational biology, applied…
Support for your Research The Research IT Technology Platform was created in 2007 to extend IT support at the Biozentrum beyond standard IT workplace solutions. Integrating and completing existing services, we provide…
According to T3 Pharmaceuticals (T3 Pharma), the funds of more than 25 million Swiss francs will be used primarily to progress the lead candidate through early clinical studies. The clinical trial in patients with solid…
This website uses cookies to collect data from users and improve functionality. By continuing to browse the site you are agreeing to this. Receive more information by reading our privacy policy.